



Marshfield Medical Center

2019 Outpatient Cumulative Antibigram

Contact Dr. Thomas Novicki or Dr. Thomas Fritsche at ext. 16300 (715-221-6300) for additional information regarding this report. Contact the Marshfield Clinic Pharmacy Drug Information Service at ext. 19800 (715-221-9800) for dosing and other drug information.

% Susceptible	<i>Citrobacter freundii</i>	<i>Enterobacter cloacae</i>	<i>Escherichia coli</i>	<i>Haemophilus influenzae (IP/OP)</i>	<i>Klebsiella pneumoniae</i>	<i>Klebsiella (Enterobacter) aerogenes</i>	<i>Klebsiella oxytoca</i>
Maximum # Tested	80	98	3625	119	424	55	109
Amikacin	100%	100%	100%	-	100%	100%	100%
Gentamicin	96%	100%	96%	-	99%	100%	100%
Tobramycin	99%	100%	97%	-	100%	100%	100%
Ampicillin	0%	0%	68%	63%	0%	0%	0%
Ampicillin/ Sulbactam	76%	33%	75%	-	91%	47%	51%
Piperacillin/ Tazobactam	94%	89%	99%	-	99%	93%	100%
Aztreonam	86%	87%	97%	-	98%	87%	99%
Cefazolin	0%	0%	69%	-	85%	0%	5%
Ceftazidime	86%	88%	98%	-	99%	85%	99%
Ceftriaxone	83%	84%	96%	-	98%	84%	99%
Cefepime	100%	99%	100%	-	100%	100%	100%
Meropenem	100%	100%	100%	-	100%	100%	100%
Ciprofloxacin	99%	100%	90%	-	99%	100%	100%
Levofloxacin	100%	100%	90%	-	99%	100%	100%
Tetracycline	89%	95%	84%	-	88%	93%	94%
Minocycline	88%	93%	95%	-	90%	93%	98%
Nitrofurantoin	99%	70%	99%	-	91%	89%	98%
Trimethoprim/ Sulphamethoxazole	86%	93%	86%	-	95%	98%	97%

IP/OP, combined inpatient and outpatient data.

% Susceptible	<i>Morganella morganii</i>	<i>Proteus mirabilis</i>	<i>Pseudomonas aeruginosa</i>	<i>Serratia marcescens</i>	<i>Stenotrophomonas maltophilia (IP/OP)</i>
Maximum # Tested	35	204	268	44	28
Amikacin	100%	100%	99%	100%	-
Gentamicin	94%	90%	97%	100%	-
Tobramycin	97%	93%	99%	100%	-
Ampicillin	0%	0%	0%	0%	-
Ampicillin/ Sulbactam	23%	98%	0%	11%	-
Piperacillin/ Tazobactam	100%	100%	97%	100%	-
Aztreonam	100%	100%	92%	100%	-
Cefazolin	0%	0%	0%	0%	-
Ceftazidime	94%	100%	99%	100%	72%
Ceftriaxone	94%	100%	0%	89%	-
Cefepime	100%	100%	98%	100%	-
Meropenem	100%	100%	97%	100%	-
Ciprofloxacin	91%	84%	93%	91%	-
Levofloxacin	97%	86%	89%	91%	93%
Tetracycline	63%	0%	0%	14%	-
Minocycline	54%	0%	0%	89%	100%
Nitrofurantoin	0%	0%	0%	0%	-
Trimethoprim/ Sulphamethoxazole	91%	87%	0%	100%	100%

IP/OP, combined inpatient and outpatient data.

% Susceptible	<i>Enterococcus faecalis</i>	<i>Enterococcus faecium</i>	<i>Staphylococcus aureus*</i>	<i>Staphylococcus epidermidis*</i>	<i>Staphylococcus lugdunensis*</i>	<i>Streptococcus anginosus grp</i>	<i>Streptococcus pneumoniae (IP/OP)</i>
Maximum # Tested	457	27	975	386	46	22	33
Ampicillin	100%	30%	-	-	-	-	-
Penicillin	100%	26%	24%	17%	57%	100%	-
Penicillin (Oral)	-	-	-	-	-	-	67%
Penicillin(meningitis)	-	-	-	-	-	-	67%
Penicillin(nonmeningitis)	-	-	-	-	-	-	97%
Oxacillin	-	-	76%	43%	100%	-	-
Ceftaroline	-	-	100%	-	-	-	-
Ceftriaxone	-	-	-	-	-	100%	-
Ceftriaxone (meningitis)	-	-	-	-	-	-	88%
Ceftriaxone (nonmeningitis)	-	-	-	-	-	-	97%
Cefepime	-	-	-	-	-	-	94%
Meropenem	-	-	-	-	-	100%	85%
Clindamycin	-	-	83%	34%	87%	91%	88%
Erythromycin	-	-	61%	1%	3%	82%	70%
Daptomycin	100%	100%	100%	100%	100%	-	-
Levofloxacin	82%	35%	76%	48%	100%	100%	100%
Linezolid	100%	100%	100%	100%	100%	100%	100%
Nitrofurantoin	99%	80%	99%	99%	94%	-	-
Tetracycline	23%	22%	92%	83%	98%	-	85%
Trimethoprim/ Sulphamethoxazole	-	-	98%	-	-	-	70%
Vancomycin	100%	59%	100%	100%	100%	100%	100%

* Staphylococcal susceptibility to oxacillin predicts susceptibility to all anti-staphylococcal penicillins, cephalosporins, carbapenems, and beta lactam/ beta lactamase inhibitor combination drugs.

IP/OP, combined inpatient and outpatient data.